secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ensysce Biosciences, Inc. (ENSC)
CIK:        0001716947
Form:       8-K
Filed at:   2024-05-13T23:59:59+00:00
Accession:  0001493152-24-018793
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ensysce Biosciences reports Q1 net loss of $3.1M; advances PF614 Phase 3 plans
------------------------------------------------------------------------------

- Net loss attributable to common stockholders was $3.1M for Q1 2024, vs $2.2M in Q1 2023.
- Cash increased to $3.4M at March 31, 2024 from $1.1M at Dec 31, 2023, boosted by $6.8M in warrant exercises.
- R&D expenses decreased to $0.8M from $1.8M YoY; G&A decreased to $1.4M from $1.6M.
- FDA granted Breakthrough Therapy designation for PF614-MPAR in January; Phase 3 trial for PF614 expected to start H2 2024.
- Federal grant revenue fell to $0.3M from $0.8M due to completion of MPAR grant in Dec 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1716947/000149315224018793/0001493152-24-018793-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1716947/000149315224018793/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-018793

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer